Business
BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™
New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patientsBURLINGTON, Mass. and JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that Highmark Blue Cross Blue Shield®, a company with over seven million covered lives that primarily serves Pennsylvania, Delaware, West Virginia, and parts of New Y
About this update from Brainsway Ltd
[{"type":"image","alt":"BrainsWay","displaySize":"","headline":null,"caption":"BrainsWay","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":219,"url":"https://media.zenfs.com/en/globenewswire.com/c68c48f9a0ccb3343f1124cb0b8b7c2f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6QrLgY5gLW7VtP5hZFuKtg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c68c48f9a0ccb3343f1124cb0b8b7c2f","width":300,"height":219}},"lazy":false},{"type":"text","content":"New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patients","length":110,"tagName":"p"},{"type":"text","content":"BURLINGTON, Mass. and JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that Highmark Blue Cross Blue Shield®, a company with over seven million covered lives that primarily serves Pennsylvania, Delaware, West Virginia, and parts of New York, has released a draft medical policy which, among other developments, expands coverage to include adolescent and adult patients with major depressive disorder (MDD) treated with the company’s accelerated Deep TMS™ protocol.","length":621,"tagName":"p"},{"type":"text","content":"The policy, which is anticipated to go into effect in February 2026 after an open comment period, will provide coverage of BrainsWay’s accelerated SWIFT™ (Short-course with Intrinsic Field Targeting) protocol, which consists of an acute phase of five treatment sessions (ten minutes each) per day for six days, followed by two sessions per day once a week for four weeks, for a total of 38 sessions. Accelerated Deep TMS does not entail the use of any functional MRI or other expensive neuronavigational equipment.","length":514,"tagName":"p"},{"type":"text","content":"“We believe this news from Highmark, together with our recently reported adoption by another payer of a medical policy covering our accelerated protocol, will help usher in a new era in Deep TMS depression treatment. This trend affords patients increased flexibility by giving them access to a treatment option requiring considerably fewer visits to the clinic,” stated Scott Blackman, Director of Market Access for BrainsWay.","length":431,"...